BPC-157

01

Investigation

What is being claimed?

“Wolverine peptide,” miraculous soft-tissue repair, oral for gut / injection for joints, “safe because natural,” stacks with TB-500. Forums treat scarce published harms as proof of safety.

02

Investigation

What the landscape contains

Abundant: preclinical literature across tendon, ligament, muscle, wound, GI, vascular models. Mechanistic themes explain why enthusiasm is not random.

Thin: human clinical evidence for popular recovery claims. No completed published randomized placebo-controlled efficacy trials identified for those uses. Commonly cited human reports are small uncontrolled pilots. Sports-medicine reviews keep finding preclinical majority vs minimal clinical inclusion.

Not yet: NCT07437547, a recruiting Phase 2 RCT for grade II hamstring strain. The question is becoming properly askable. It is not answered.

Outside journals, still real: not FDA-approved; WADA prohibition; product identity/purity concerns in gray channels. Compounding is still not lawful under 503A as of August 2026. FDA staff recommended against adding BPC-157 to the Bulks List; the Pharmacy Compounding Advisory Committee then voted 8–6 with 1 abstention to recommend inclusion. That vote is advisory. It isn’t approval, and it doesn’t make compounding legal. Rulemaking has not finished.

03

Investigation

What we should conclude today

• Interesting preclinical signal. Not imaginary.
• Not clinically established for the recovery indications dominating patient conversation.
• Absence of published RCTs is the central clinical fact.
• Tiny pilots cannot carry forum certainty.
• Human safety is incompletely characterized at approved-drug standards.
• Use can be common while evidence is immature.
• Watch serious trials. Update when the landscape changes.

Neither “rodents healed, so it works” nor “uncertain, so anyone using it is foolish” fits the evidence shape.

04

Investigation

Why should an RD care?

You will rarely “prescribe BPC-157.” You will meet people already using or considering it while a tendon stalls.

Evidence-anchored work still exists: energy availability, protein, sleep, alcohol, graded loading with rehab. Under-fueling and early return-to-play sabotage healing more reliably than any unapproved peptide has been shown to rescue it.

Translate categories without condescension. Keep rehab in the room. Ask about source. Separate stacks. Name anti-doping early. Respect hope without inflating evidence.

Usable line: “There is a substantial animal research story and very little high-quality human trial evidence for the recovery uses people talk about. It isn’t FDA-approved, and tested athletes generally can’t use it. What we can do well together is protect your healing environment: fuel, protein, sleep, and rehab.”